核应急医学救援专用药品的储备与管理思考

摘要/Abstract

摘要： 结合近几年军地开展核应急医学救援演训所需专用药品的现状,对核应急医学救援中抗放药物、促排药物、阻吸收药物以及止吐止泻药物进行分类介绍,并对如何储备和管理进行深入探讨。

Abstract: Based on the current situation of special drugs required by the exercises and training for military and civilian nuclear emergency medical rescue in recent years, this paper introduces the classification of anti-radioactive drugs, excretion promoting drugs, anti-absorption drugs, anti-emetic drugs and anti-diarrheal drugs in nuclear emergency medical rescue. Methods on how to reserve and manage them are discussed in depth.

Key words: Nuclear emergency medical rescue, Special drugs, Storage, Management

中图分类号:

TL73

朱磊, 郭姗姗, 杨超, 白帆, 刘明浩, 王佳楠. 核应急医学救援专用药品的储备与管理思考[J]. 辐射防护通讯, 2023, 43(2): 8-15.

Zhu Lei, Guo Shanshan, Yang Chao, Bai Fan, Liu Minghao, Wang Jianan. Consideration on the Storage and Management of Special Drugs for Nuclear Emergency Medical Rescue[J]. RADIATION PROTECTION BULLETIN, 2023, 43(2): 8-15.

参考文献

[1] 王佳,尤斯涵,郭春燕. 急性放射病防治药物的研究进展[J].神经药理学报,2021,11(3):25-32.
[2] 张俊伶,路璐,李德冠,等. 四种雌激素对放射性造血损伤防护效应的比较[J].中国医药导报,2015,12(10):4-6.
[3] 刘瑾,李文辉,翟光胜. 茜草醇提物对辐射损伤小鼠造血系统保护作用的研究[J]. 中国癌症防治,2016,8(3):145-149.
[4] 李娜,陈方,欧伦,等. 聚乙二醇重组人粒细胞集落刺激因子对猕猴辐射致粒细胞减少症的治疗作用[J]. 中国药理学与毒理学杂,2012,26(1):78-82.
[5] 艳梅,田伟,王焕坤,等. 氨磷汀防辐射应用现状及发展趋势[J].临床军医杂志,2022,50(4):437-440.
[6] Amgen Inc. NPLATEVR (romiplostim) for injection, for subcutaneoususe[R/O]. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125268s167lbl.pdf.
[7] Bussel J B, Soff G, Balduzzi A, et al. A review of romiplostim mechanism of action and clinical applicability[J]. Drug Des Devel Ther, 2021, 15:2243-2268. doi: 10.2147/DDDT. S299591.
[8] Singh V K, Seed T M. Radiation countermeasures for hematopoietic acute radiation syndrome: growth factors, cytokines and beyond[J]. Int J Radiat Biol, 2021, 97(11):1526-1547. doi: 10.1080/09553002.2021.1969054.
[9] International Atomic Energy Agency, International Federation of Red Cross and Red Crescent Societies, Pan American Health Organization. Medical management of persons internally contaminated with radionuclides in a nuclear or radiological emergency: a manual for medical personnel[R]. Vienna: International Atomic Energy Agency, 2018. https://www-pub.iaea.org/MTCD/Publications/PDF/EPR-Contamination_web.pdf.
[10] Tominaga T, Shimomura S, Tanosaki S, et al. Effects of the chelating agent DTPA on naturally accumulating metals in the body[J]. Toxicol Lett, 2021, 350:283-291. doi: 10.1016/j.toxlet.2021.08.001.
[11] Ohmachi Y, Imamura T, Ikeda M, et al. Sodium bicarbonate protects uranium-induced acute nephrotoxicity through uranium-decorporation by urinary alkalinization in rats[J]. J Toxicol Pathol, 2015, 28(2):65-71. doi: 10.1293/tox.2014-0041.
[12] MacVittie T J, Farese A M, Parker G A, et al. The gastrointestinal subsyndrome of the acute radiation syndrome in rhesus macaques: a systematic review of the lethal dose-response relationship with and without medical management[J]. Health Phys, 2019, 116(3):305-338. doi: 10.1097/hp.00000000000000903.
[13] International Atomic Energy Agency. The radiological accident in Goiânia[R/O]. 1988. http://www-pub.iaea.org/MTCD/publications/PDF/Pub815_web.pdf.
[14] Department of Homeland Security. National planning scenarios, version 21.3 2006 final draft. d for use in national, federal, state, and local homeland security preparedness activities[R/O]. 2010. https://publicintelligence.net/national-planning-scenarios-version-21-3-2006-final-draft/.
[15] Federal Emergency Management Agency. Improvised nuclear device response and recovery: communicating in the immediate aftermath[R/O]. Washington DC, 2013. https://www.samhsa.gov/resource/dbhis/improvised-nuclear-device-response-recovery-communicating-immediate-aftermath.
[16] Radiation Protection Division, Office of Radiation and Indoor Air. PAG manual: Protective action guides and planning guides for radiological incidents[R/O]. Washington DC, 2017. https://www.epa.gov/sites/default/files/2017-01/documents/epa_pag_manual_final_revisions_01-11-2017_cover_disclaimer_8.pdf.
[17] Gianfredi V, Filia A, Rota M C, et al. Vaccine procurement: a conceptual framework based on literature review[J]. Vaccines (Basel), 2021, 9(12):1434. doi: 10.3390/vaccines9121434.
[18] Coleman C N, Hrdina C, Casagrande R, et al. User-managed inventory: an approach to forward-deployment of urgently needed medical countermeasures for mass-casualty and terrorism incidents[J]. Disaster Med Public Health Prep, 2012, 6(4):408-414. doi: 10.1001/dmp.2012.46a.
[19] Yen C, Hyde T B, Costa A J, et al. The development of global vaccine stockpiles[J]. Lancet Infect Dis, 2015, 15(3):340-347. doi: 10.1016/S1473-3099(14)70999-5.
[20] Abergel R J, Durbin P W, Kullgren B, et al. Biomimetic actinide chelators: an update on the preclinical development of the orally active hydroxypyridonate decorporation agents 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO)[J]. Health Phys, 2010, 99(3):401-407. doi: 10.1097/ HP.0b013e33181c21273.
[21] Cassatt D R, Kaminski J M, Hatchett R J, et al. Medical countermeasures against nuclear threats: radionuclide decorporation agents[J]. Radiat Res, 2008, 170(4):540-548. doi: 10.1667/rr1485.1.
[22] Cohen E P, Fish B L, Moulder J E. Clinically relevant doses of enalapril mitigate multiple organ radiation injury[J]. Radiat Res, 2016, 185(3):313-318. doi: 10.1667/RR4243.S1.
[23] Holecki M, Szewieczek J, Chudek J. Effects of angiotensin-converting enzyme inhibitors beyond lowering blood pressure-are they important for doctors?[J]. Pharmacol Rep, 2011, 63(3):740-751. doi: 10.1016/S1734-1140(11)70586-2.
[24] Cohen E P, Bedi M, Irving A A, et al. Mitigation of late renal and pulmonary injury after hematopoietic stem cell transplantation[J]. Int J Radiat Oncol Biol Phys, 2012, 83(1):292-296. doi: 10.1016//j.ijrobp.2011.05.081.